JPMorgan Chase & Co’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $382K | Sell |
19,064
-2,701
| -12% | -$54.2K | ﹤0.01% | 4174 |
|
|
2025
Q1 | $428K | Buy |
21,765
+2,020
| +10% | +$39.8K | ﹤0.01% | 4105 |
|
|
2024
Q4 | $444K | Sell |
19,745
-1,062
| -5% | -$23.9K | ﹤0.01% | 4203 |
|
|
2024
Q3 | $531K | Buy |
20,807
+13
| +0.1% | +$332 | ﹤0.01% | 3979 |
|
|
2024
Q2 | $486K | Buy |
20,794
+2,407
| +13% | +$56.3K | ﹤0.01% | 3875 |
|
|
2024
Q1 | $323K | Sell |
18,387
-5,602
| -23% | -$98.5K | ﹤0.01% | 4206 |
|
|
2023
Q4 | $332K | Sell |
23,989
-2,506
| -9% | -$34.7K | ﹤0.01% | 4125 |
|
|
2023
Q3 | $362K | Sell |
26,495
-4,160
| -14% | -$56.8K | ﹤0.01% | 3891 |
|
|
2023
Q2 | $626K | Buy |
30,655
+30,561
| +32,512% | +$624K | ﹤0.01% | 3667 |
|
|
2023
Q1 | $2K | Buy |
+94
| New | +$2K | ﹤0.01% | 5545 |
|
|
2022
Q4 | – | Sell |
-2
| Closed | – | – | 5656 |
|
|
2022
Q3 | $0 | Buy |
+2
| New | – | ﹤0.01% | 5590 |
|
|
2021
Q4 | – | Sell |
-2,037
| Closed | -$33K | – | 5750 |
|
|
2021
Q3 | $33K | Sell |
2,037
-486
| -19% | -$7.87K | ﹤0.01% | 5041 |
|
|
2021
Q2 | $80K | Sell |
2,523
-2,730
| -52% | -$86.6K | ﹤0.01% | 4832 |
|
|
2021
Q1 | $177K | Buy |
5,253
+124
| +2% | +$4.18K | ﹤0.01% | 4497 |
|
|
2020
Q4 | $453K | Buy |
5,129
+4,352
| +560% | +$384K | ﹤0.01% | 3804 |
|
|
2020
Q3 | $68K | Sell |
777
-280
| -26% | -$24.5K | ﹤0.01% | 4196 |
|
|
2020
Q2 | $117K | Buy |
+1,057
| New | +$117K | ﹤0.01% | 3891 |
|